DeepMed Research

BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

Phase 3

Completed

Conditions: Children
Contrast Enhancement in Magnetic Resonance Imaging

Interventions: Drug: Gadoquatrane (BAY1747846)

First Posted Date: 2023-06-22

Last Posted Date: 2024-10-29

Lead Sponsor: Bayer

Target Recruit Count: 93

Registration Number: NCT05915026

Locations: 🇺🇸
Halo Diagnostics, Indian Wells, California, United States
🇺🇸
Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States
🇺🇸
Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension, Cincinnati, Ohio, United States

and more 35 locations

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

Phase 3

Active, not recruiting

Conditions: Chronic Kidney Disease
Type 1 Diabetes Mellitus

Interventions: Drug: Finerenone
Other: Placebo

First Posted Date: 2023-06-13

Last Posted Date: 2025-05-08

Lead Sponsor: Bayer

Target Recruit Count: 220

Registration Number: NCT05901831

Locations: 🇪🇸
Hospital Gregorio Maranon | Endocrinology Department, Madrid, Spain
🇺🇸
Elixia Central Florida, Orlando, Florida, United States
🇨🇳
The Central Hospital of Wuhan, Tongji Medl Collg Huazhong..., Wuhan, Hubei, China

and more 78 locations

A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)

Not yet recruiting

Conditions: Venous Thromboembolism
Children Under 2 Years

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Standard of care (SOC)

First Posted Date: 2023-06-12

Last Posted Date: 2025-05-08

Lead Sponsor: Bayer

Target Recruit Count: 850

Registration Number: NCT05900388

Locations: 🇸🇪
Many locations, Multiple Locations, Sweden

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors
Non-small Cell Lung Cancer

Interventions: Drug: BAY2862789

First Posted Date: 2023-05-15

Last Posted Date: 2025-05-22

Lead Sponsor: Bayer

Target Recruit Count: 69

Registration Number: NCT05858164

Locations: 🇺🇸
AdventHealth medical Group Oncology Research at Celebration, Celebration, Florida, United States
🇺🇸
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan, United States
🇺🇸
University of Mississippi Medical Center | Shafi Group, Jackson, Mississippi, United States

and more 15 locations

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Phase 3

Active, not recruiting

Conditions: Macular Edema Secondary to Retinal Vein Occlusion

Interventions: Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham
Diagnostic Test: Fluorescein

First Posted Date: 2023-05-09

Last Posted Date: 2025-05-04

Lead Sponsor: Bayer

Target Recruit Count: 892

Registration Number: NCT05850520

Locations: 🇹🇷
Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey
🇹🇷
Adnan Menderes Universitesi Tip fakultesi, Aydin, Turkey
🇹🇷
Ankara Bilkent Sehir Hastanesi, Bilkent Ankara, Turkey

and more 271 locations

An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions

Active, not recruiting

Conditions: Metastatic Colorectal Cancer (mCRC)

Interventions: Drug: Regorafenib (BAY73-4506, Stivarga®)
Drug: TAS-102 (trifluridine and tipiracil, Lonsurf®)
Drug: Bevacizumab

First Posted Date: 2023-05-03

Last Posted Date: 2025-04-17

Lead Sponsor: Bayer

Target Recruit Count: 818

Registration Number: NCT05839951

Locations: 🇺🇸
Many locations, Whippany, New Jersey, United States

A Study to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body, How it Moves Into, Through and Out of the Body When Single and Multiple Amounts Are Taken as Tablets in Japanese Healthy Male Participants

Phase 1

Completed

Conditions: Chronic Kidney Disease
Healthy Volunteers

Interventions: Other: Placebo
Drug: BAY3283142

First Posted Date: 2023-04-05

Last Posted Date: 2023-08-21

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT05800444

Locations: 🇯🇵
SOUSEIKAI Fukuoka Mirai Hospital, Fukuoka, Japan

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Phase 3

Recruiting

Conditions: Biochemically Recurrent Prostate Cancer

Interventions: Drug: Darolutamide (BAY1841788, Nubeqa)
Other: Placebo matching darolutamide
Other: ADT

First Posted Date: 2023-04-03

Last Posted Date: 2025-05-08

Lead Sponsor: Bayer

Target Recruit Count: 970

Registration Number: NCT05794906

Locations: 🇪🇸
Hospital Fundació Puigvert, Barcelona, Spain
🇵🇱
Centrum Medyczne iMed24, Krakow, Poland
🇵🇱
Medrise Sp. z o.o. Centrum Badan Klinicznych, Lublin, Poland

and more 297 locations

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Completed

Conditions: Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Interventions: Other: No Drug

First Posted Date: 2023-03-31

Last Posted Date: 2023-10-25

Lead Sponsor: Bayer

Target Recruit Count: 46621

Registration Number: NCT05793281

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China

Recruiting

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Vericiguat (Verquvo, BAY1021189)
Drug: Standard of Care (SoC)

First Posted Date: 2023-02-15

Last Posted Date: 2025-04-30

Lead Sponsor: Bayer

Target Recruit Count: 2400

Registration Number: NCT05728502

Locations: 🇨🇳
Chinese Registries, Multiple Locations, Many Locations, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy